Italia markets open in 8 hours 13 minutes

BioNTech SE (BNTX)

NasdaqGS - NasdaqGS Prezzo in tempo reale. Valuta in USD.
Aggiungi a portafoglio
156,49+5,51 (+3,65%)
Alla chiusura: 04:00PM EST
158,63 +2,14 (+1,37%)
Dopo ore: 06:45PM EST

BioNTech SE

An der Goldgrube 12
Mainz 55131
Germany
49 6131 9084 0
https://www.biontech.de

Settore/iHealthcare
SettoreBiotechnology
Impiegati a tempo pieno2.800

Figure dirigenziali chiave

NomeTitoloRetribuzioneEsercitateAnno di nascita
Prof. Ugur Sahin M.D.Co-Founder, CEO & Member of Management Board684,98kN/D1966
Prof. Christoph Hubert Huber M.D., Ph.D.Co-Founder & Member of Supervisory BoardN/DN/D1945
Dr. Sierk Poetting Ph.D.MD, COO & Member of Management Board690,65kN/D1974
Mr. Ryan RichardsonChief Strategy Officer, MD & Member of Management Board609kN/D1980
Mr. Sean MarettChief Bus. Officer, Chief Commercial Officer & Member of Management Board764,37kN/D1966
Dr. Ozlem Tureci M.D.Chief Medical Officer & Member of Management Board678,18kN/D1968
Mr. Jens H. HolsteinCFO & Member of Management BoardN/DN/D1963
Sylke Maas Ph.D.VP of Investor Relations and Bus. StrategyN/DN/DN/D
Dr. James Timothy Patrick Ryan Ph.D.VP of Legal & Intellectual PropertyN/DN/DN/D
Michael BoehlerMD & Head of Global External CommunicationsN/DN/DN/D
Gli importi risalgono al giorno 31 dicembre 2020 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is involved in the developing of FixVac product candidates, including BNT111, which is in Phase I clinical trial for advance melanoma; BNT112 that is in Phase I/IIa trial for prostate cancer; BNT113, which is in Phase I/II trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115 in a Phase I trial in ovarian cancer; and BNT116 for non-small cell lung cancer.It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase I clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT153 for multiple solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT221 for other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II a clinical trial to treat multiple solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody, which is in Phase I/IIa clinical trial for pancreatic cancer; BNT411, small molecule immunomodulator product candidate for solid tumors; prophylactic vaccine for COVID-19 and Influenza; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Genevant Sciences GmbH; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; and Regeneron Pharmaceuticals, Inc. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.

Governance aziendale

L'ISS Governance QualityScore di BioNTech SE al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.